𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results

✍ Scribed by Nithi Mahanonda; Kiertijai Bhuripanyo; Charuwan Kangkagate; Kanchana Wansanit; Bang-on Kulchot; Koonlawee Nademanee; Suphachai Chaithiraphan

Book ID
115660454
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
438 KB
Volume
130
Category
Article
ISSN
1097-6744

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Rituximab in patients with primary progr
Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
✍ Kathleen Hawker; Paul O'Connor; Mark S. Freedman; Peter A. Calabresi; Jack Antel πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 158 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab, a monoclonal antibody selectively depleting CD20+ B cells, has demonstrated efficacy in reducing disease activity in relapsing‐remitting multiple sclerosis (MS). We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety thro

Efficacy and safety of golimumab in pati
Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
✍ Robert D. Inman; John C. Davis Jr.; DΓ©sirΓ©e Van Der Heijde; Laura Diekman; Joach πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 168 KB πŸ‘ 2 views

## Abstract ## Objective To evaluate the efficacy and safety of golimumab in patients with ankylosing spondylitis (AS) in the GO‐RAISE study. ## Methods Patients with active AS, a Bath AS Disease Activity Index (BASDAI) score β‰₯4, and a back pain score of β‰₯4 were randomly assigned in a 1.8:1.8:1